In the phase IIa MyPathway basket trial, a dual-antibody regimen consisting of pertuzumab and trastuzumab produced an ORR of 23% and a median PFS of 4.0 months in 39 patients with HER2-amplified and/or overexpressing CCA [145], leading to its inclusion in the NCCN guidelines as a recommended option for previously treated HER2-positive CCA. This evidence concerns the gene ERBB2 and cholangiocarcinoma.